Opendata, web and dolomites

AGLYC SIGNED

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AGLYC project word cloud

Explore the words cloud of the AGLYC project. It provides you a very rough idea of what is the project "AGLYC" about.

smei    diseases    02    86    closed    estimate    global    hospital    glycardial    ischemic    october    completion    morbidity    2017    detection    23    mins    plan    spanish    sant    creu    accounting    la    2015    acute    necrosis    living    bn    de    expenses    cardiac    tests    iccc    event    lives    death    cover    pau    founded    sensitivity    total    model    166    98    cagr    ir    market    santa    absence    detecting    vision    sales    ischemia    events    deaths    patients    cvd    sublicense    either    93    company    competitive    diagnosis    laboratory    almost    onset    represented    64    irreversible    tissue    87    business    ivd    medtech    effectiveness       progression    advantages    valued    49    cardiovascular    nearly    15    diagnostics    spin    gt    national    heart    vitro    medical    diagnostic    projected    globe    council    damage    europeans    aglyc    off    round    pharmaceutical    first    disease    lab    device    successful    prevent    65    society    ebitda    demonstrates    31    2023    reducing   

Project "AGLYC" data sheet

The following table provides information about the project.

Coordinator
GLYCARDIAL DIAGNOSTICS, SL 

Organization address
address: CALLE BALDIRI REIXAC 48 - PLANTA 1 PUERTA B04 PARC CIENTIFIC DE BARCELONA TORRE R
city: BARCELONA
postcode: 8028
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 2˙727˙139 €
 EC max contribution 1˙908˙997 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCARDIAL DIAGNOSTICS, SL ES (BARCELONA) coordinator 1˙908˙997.00

Map

 Project objective

Cardiovascular diseases (CVD) are the leading cause of death/morbidity across the globe, accounting for 31% of all deaths in 2015. In the same year almost 49 m Europeans were living with CVD. Early detection of ischemia is essential to prevent the progression of heart damage and the irreversible tissue damage (necrosis) that can lead to heart failure.

AGLYC is an IVD lab-based test for the early detection of ischemia (15 mins event onset) in the absence of the irreversible necrosis of the tissue. AGLYC demonstrates a 98% sensitivity in detecting the presence of ischemic heart disease. Our main competitive advantages are high sensitivity, early detection of ischemia, and cost effectiveness.

The global in vitro diagnostics (IVD) market was valued at $64.02 bn in 2017 and is projected to reach $87.93 bn by 2023, at a CAGR of 5.2%. The laboratory diagnostic test (lab-based) market represents 86% of the total diagnostic testing market. Specifically, the market for lab tests related to acute cardiac ischemic events represented about $166 m in total sales in 2015. We have estimated a lab-based target market of >70 m patients.

Our main business model will be a sublicense model based on the development of a laboratory-based test that we will develop and then sublicense to either a medical device company (MedTech) or to a pharmaceutical company. With this model and the successful completion of the SMEI phase 2 we estimate an EBITDA of around €23 m.

The company closed a first funding round of €2.4 m on October 2017 to cover nearly 65% of the expenses of the development plan. GlyCardial Diagnostics, S.L. was founded in 2017 as a spin-off of the ICCC- IR-Hospital de la Santa Creu i Sant Pau and the Spanish National Research Council with the focus of developing a novel IVD test for cardiac ischemia. Our vision is to improve the early diagnosis of cardiac ischemic events, reducing the impact of the disease on patients’ lives and society as a whole.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AGLYC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AGLYC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MCBD (2019)

MCBD (MULTI-CORE BIOPSY DEVICE) INNOVATIVE BIOPSY TECHNOLOGY FOR THE NEW ERA OF TARGETED MEDICINE

Read More  

SmartDegrees (2020)

First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain

Read More  

ALICE (2019)

Armored Liftable anti-Intrusion Control Equipment

Read More